Home » Creatinine Clearance

Creatinine Clearance Calculator

The below tool is a resource you can use to calculate a patient’s Creatinine Clearance (CrCl) using the patient’s gender, their actual body weight (in kilograms), and their Serum Creatinine levels (in mg/dL).

This calculator uses the Cockcroft-Gault equation. All calculations should be confirmed and reassessed before use.


Based on the parameters provided, this patient's creatinine clearance (CrCl) is mL/min.

Label Dosing & Administration

Administer AGGRASTAT intravenously 25 mcg/kg within 5 minutes and then mcg/kg/min for up to 18 hours.

Download the Dosing & Administration Guide for AGGRASTAT®

A dose adjustment is required for patients with severe renal insufficiency (defined as creatinine clearance <60 mL/min). For these patients, reduce the maintenance infusion of AGGRASTAT to 0.075 mcg/kg/min for up to 18 hours. The bolus dose is not adjusted. Creatinine Clearance is calculated using the Cockcroft-Gault equation.


This calculator uses the Cockcroft-Gault equation. All calculations should be confirmed and reassessed before use. By using this resource, you agree to the following: This calculator is being provided “AS IS” and is intended for use only by qualified healthcare providers. All calculations should be confirmed before use. Medicure makes no claims as to the accuracy of the information contained herein. The information being provided is not a substitute for clinical judgment. Neither Medicure, nor any other party involved in the preparation or publication of this site, shall be liable to you or others for any decisions made or actions taken by you or others in reliance on this information.

Important Safety Information


Aggrastat® is indicated to reduce the rate of thrombotic cardiovascular events (combined endpoint of death, myocardial infarction, or refractory ischemia/repeat cardiac procedure) in patients with non-ST elevation acute coronary syndrome (NSTE-ACS).


  • Known hypersensitivity to any component of Aggrastat®.
  • History of thrombocytopenia with prior exposure to Aggrastat®.
  • Active internal bleeding, or history of bleeding diathesis, major surgical procedure or severe physical trauma within the previous month.

Warnings and Precautions:

  • Aggrastat® can cause serious bleeding. Most bleeding associated with Aggrastat® occurs at the arterial access site for cardiac catheterization. Minimize the use of traumatic or potentially traumatic procedures such as arterial and venous punctures, intramuscular injections, nasotracheal intubation, etc. Concomitant use of fibrinolytics, anticoagulants and antiplatelet drugs increases the risk of bleeding. If bleeding cannot be controlled, discontinue Aggrastat®.
  • Thrombocytopenia: discontinue Aggrastat® and heparin.

Adverse Reactions:

  • Bleeding is the most commonly reported adverse reaction.

For additional information, refer to the full Prescribing Information.

You are encouraged to report negative side effects of prescription drugs to the FDA.

Visit www.FDA.gov/medwatch
or call 1-800-FDA-1088.